In 2025, the beta-glucans from Yeast market crossed a valuation of USD 338.0 million. Based on Future Market Insights’ analysis, demand is estimated to grow to USD 362.5 million in 2026 and USD 845.0 million by 2036. FMI projects a CAGR of 9.0% during the forecast period. According to FMI's estimates, procurement shifts toward verified yeast beta glucan suppliers capable of passing strict safety reviews. Buyers prioritize clinical substantiation over generic botanical extracts.
Stricter compliance standards are redefining baseline formulation requirements across the nutrition industry. The U.S. Food and Drug Administration set a 200 mg per serving threshold for baker’s yeast beta glucan extracts [3], creating clearer guidance for manufacturers. This regulatory clarity simplifies sourcing decisions and lowers uncertainty for formulators seeking compliant, clinically supported ingredients. As a result, companies with integrated supply chains and scalable bio-fermented beta glucan production are well positioned to capture greater value in premium dietary supplement segments.
| Metric | Details |
| Industry Size (2026) | USD 362.5 million |
| Industry Value (2036) | USD 845.0 million |
| CAGR (2026-2036) | 9.0% |
"The expansion through our biotechnology facility marks a new era for Layn Natural Ingredients, allowing us to push the boundaries of precision fermentation and enzyme production," said James Roza, chief scientific officer at Layn Natural Ingredients.1 "With Galacan, we are redefining beta glucan innovation, offering enhanced bioavailability and functional benefits for supplements, foods and beverages, as well as excellent applications in beauty, personal care and animal nutrition." [11]
Geographic expansion aligns with escalating immunomodulatory ingredient requirements across human and animal nutrition. Global aquaculture production reached 130.9 million tonnes recently, elevating veterinary additive consumption. [5] Across India, China, United States, United Kingdom, Brazil, and Germany, adoption accelerates where local safety audits align with capacity. FMI analysts opine that procurement clusters around framework agreements, favoring beta glucans alternatives and incumbent manufacturers.
Beta-glucans from Yeast sector comprises production and commercialization of complex polysaccharides extracted primarily from Saccharomyces cerevisiae cell walls. Operations involve fermentation, extraction, and purification processes yielding bioactive yeast compounds. Buyers integrate specialized extracts into nutritional supplements, functional foods, and animal feed for immunomodulatory purposes.
Coverage incorporates pure cell wall extracts, commercial formulations like MacroGard, and derived blends containing verified chemical profiles. Revenue tracking captures sales across dietary supplements, functional foods, pharmaceuticals, and specified united states yeast aquaculture applications. Analysis includes bulk powder and liquid dispersion formats.
Analysis omits compounds derived from cereals, mushrooms, or bacteria unless explicitly co-formulated with yeast-based primary active ingredients. Coverage excludes unprocessed brewer by-products lacking standardized immunomodulatory specifications. Downstream finished retail consumer goods are not quantified within chemical intermediate revenues.
Yeast-derived beta-glucans account for 71% of total share in 2026. Manufacturers favor Saccharomyces cerevisiae extracts because of their high concentration of beta-1,3/1,6 linkages, which deliver well-documented immune-modulating benefits. Producers continue to invest in advanced precision fermentation to maintain batch-to-batch consistency and meet stringent pharmaceutical-grade standards. COSCIENS Biopharma expanded its PGX manufacturing platform with commercialization targeted for the second half of 2025 [15]. Using validated beta-glucan extracts helps brands clear compliance audits more efficiently, and procurement teams prioritize standardized actives to minimize variability in finished formulations.
Formulators are responding to aging demographics and preventive health trends by incorporating concentrated polysaccharides into daily capsule formats. This sustained shift toward routine supplementation positions dietary supplements as a core demand center, accounting for 40% of total consumption in 2026. Ingredient suppliers support this expansion with documented clinical trials that validate structure-function claims on retail packaging. Recent figures show that 57.6% of U.S. adults use dietary supplements [1], reinforcing predictable volume turnover for upstream extractors. Developing specialized microbiome-focused fiber actives further strengthens exclusive vendor relationships and secures long-term supply agreements with leading brands.
Consumers seeking therapeutic outcomes increasingly bypass mass grocery outlets and turn to specialty stores and pharmacies, where trained professionals provide product guidance. These retailers require rigorous quality assurance documentation and clinical substantiation before approving shelf placement for functional supplements. Shanghai alone registered 51,536 active special food business entities [6], underscoring the scale and regulatory oversight within this channel. Elevated compliance standards effectively filter out low-quality commodity ingredients, favoring suppliers with medical-grade positioning. As a result, specialty stores and pharmacies account for 36% of total distribution share in 2026.
Preventive health adoption generates consistent bulk ingredient demand. Consumers shift away from reactive medical treatments toward daily immune-modulating routines, forcing consumer packaged goods companies to reformulate legacy product lines. Formulators require stable, documented inputs to satisfy label claims. Kerry demonstrated a cumulative dietary exposure estimate of 1.73 g/person/day for specific populations. [4] High daily intake rates create reliable baseline consumption for raw material suppliers. Extractors respond by building dedicated pharmaceutical-grade facilities to secure lucrative long-term refined functional carbohydrates supply contracts.
Strict regulatory compliance costs restrict mid-tier manufacturers from expanding cross-border operations. Diverging international safety standards force ingredient suppliers to fund separate clinical dossiers for individual regions. Navigating distinct regulations delays commercialization timelines. United Kingdom authorities reported 95,000 overdue food standards inspections in 2024, creating administrative bottlenecks. [8] Companies mitigate delays by standardizing global safety protocols and acquiring pre-certified local extraction facilities. Smaller extractors face margin compression when attempting to fund mandated localized safety trials.
Based on the regional analysis, Beta-glucans from Yeast market is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa across 40+ countries. The full report also offers market attractiveness analysis based on regional trends.
.webp "Top Country Growth Comparison Beta Glucans From Yeast Market Cagr (2026 2036)")
| Country | CAGR (2026 to 2036) |
|---|---|
| India | 10.2% |
| China | 9.8% |
| United States | 9.1% |
| United Kingdom | 8.7% |
| Brazil | 8.6% |
| Germany | 8.4% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research
Regional demand expands rapidly as regulatory bodies formalize functional food licensing pathways. Health ministries implement strict approval frameworks, favoring established manufacturers possessing complete safety dossiers. As per FMI's projection, procurement shifts toward compliant local extractors to bypass complex import restrictions. High retailer density forces brands to differentiate utilizing premium, clinically backed ingredients. Localized manufacturing capability reduces raw material lead times for domestic supplement brands.
FMI's report includes detailed growth analysis and country-wise assessment across Asia Pacific. Japan and South Korea present lucrative expansion zones due to surging functional food requirements. Suppliers must monitor localized veterinary feed regulations to capture high-volume animal nutrition contracts. Analyzing regional adoption reveals shifting brand priorities.
Market shifts from generic immune support toward regulatory-grade substantiation and formulation convenience. Brands request specialized variants suitable for gummies and ready-to-drink beverages. Ceapro and Aeterna Zentaris approved a merger in March 2024 to re-prioritize commercialization pathways. [16] Clear regulatory guidelines reduce adoption friction for beverage formulators. Extractor companies fund clinical trials to maintain premium pricing structures.
FMI's report includes detailed growth analysis and country-wise assessment across North America. Canada and Mexico present strong expansion potential due to rising functional beverage consumption. Suppliers must monitor localized approval timelines to capture emerging retail shelf space.
High trust environments reward standardized, reproducible actives and robust documentation for claims and safety. Retailers prefer ingredients possessing strong quality assurance and traceability records. Yeastup secured CHF 8.9 million funding to scale upcycled brewer extract production. [13] Expanding local capacity satisfies strict European traceability mandates and reduces brand liability risks.
FMI's report includes detailed growth analysis and country-wise assessment across Europe. France and Italy present lucrative expansion zones due to surging dermocosmetic ingredient requirements. Suppliers must monitor localized regulations to capture high-volume topical formulation contracts.
Market growth coexists with heightened enforcement and complaint volumes, elevating regulatory trust into a competitive advantage. Local brands require Anvisa-aligned quality and transparent labeling protocols. Consolidating regional infrastructure guarantees batch consistency for local supplement manufacturers.
FMI's report includes detailed growth analysis and country-wise assessment across Latin America. Mexico and Chile present strong expansion potential due to rising functional food consumption. Suppliers must monitor localized import regulations to capture emerging retail shelf space. Analyzing regional adoption reveals shifting brand priorities.
Extractor companies prioritize vertical integration to bypass volatile international shipping networks. Expanding localized precision fermentation facilities allows suppliers to guarantee batch consistency and stabilize bulk pricing. Building regional capacity secures lucrative long-term contracts with regional pharmaceutical brands and animal nutrition conglomerates.
Regulatory compliance capabilities separate premium vendors from commodity suppliers. Extractors funding proprietary clinical trials and securing GRAS notifications command higher profit margins. Presenting updated safety dossiers accelerates retail formulation adoption and justifies elevated wholesale pricing models.
Consolidation reshapes vendor networks as major conglomerates acquire specialized regional players. Acquiring established brands provides instant access to lucrative animal nutrition and dietary supplement channels. Mergers reduce administrative overhead and expand global distribution footprints rapidly.
Recent Developments
The report includes full coverage of key trends from competitive benchmarking. Some of the recent developments covered in the reports:
| Metric | Value |
|---|---|
| Quantitative Units | USD 362.5 million (2026) to USD 845.0 million (2036), at a CAGR of 9.0% |
| Market Definition | Sector comprises production and commercialization of complex polysaccharides extracted primarily from Saccharomyces cerevisiae cell walls for immunomodulatory purposes. |
| Source Segmentation | Yeast-derived beta-glucans, Others |
| Application Segmentation | Dietary Supplements, Others |
| Distribution Channel Segmentation | Specialty Stores & Pharmacies, Others |
| End-User Segmentation | Adults, Others |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa |
| Countries Covered | United States, United Kingdom, Germany, Brazil, India, China, and 40 plus countries |
| Key Companies Profiled | Lesaffre, Kerry Group, Angel Yeast, Lallemand, Biorigin, Layn Natural Ingredients, Yeastup, COSCIENS Biopharma, Associated British Foods, DSM |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid top down and bottom up market modeling validated through primary interviews with extractor producers, supported by trade data benchmarking and plant level capacity verification |
This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.
How large is the demand for Beta-glucans from Yeast in the global market in 2026?
Demand for Beta-glucans from Yeast in the global market is estimated to be valued at USD 362.5 million in 2026.
What will be the market size of Beta-glucans from Yeast in the global market by 2036?
Market size for Beta-glucans from Yeast is projected to reach USD 845.0 million by 2036.
What is the expected demand growth for Beta-glucans from Yeast in the global market between 2026 and 2036?
Demand for Beta-glucans from Yeast in the global market is expected to grow at a CAGR of 9.0% between 2026 and 2036.
Which Source is poised to lead global sales by 2026?
Yeast-derived beta-glucans is expected to be the dominant form, capturing 71% of global market share in 2026 due to clinical substantiation.
How significant is the role of Dietary Supplements in driving Beta-glucans from Yeast adoption in 2026?
Dietary Supplements represent a critical segment, projected to hold 40% share of total volume in 2026 as preventive health activity prioritizes cost-effective materials.
What is driving demand in India?
Pharmacy-led distribution channels and professional medical recommendations are driving growth.
What compliance standards or regulations are referenced for United States?
FDA GRAS emission regulations are referenced as key compliance benchmarks.
What is the United States growth outlook in this report?
United States is projected to grow at a CAGR of 9.1% during 2026 to 2036.
Why is Europe described as a priority region in this report?
Growth is constrained by elevated compliance costs and increasing penetration of audited extraction alternatives in premium applications.
What type of demand dominates in Europe?
Replacement driven demand for premium grade, high consistency extracts dominates regional consumption.
What is China growth outlook in this report?
China is projected to expand at a CAGR of 9.8% during 2026 to 2036.
Does the report cover United Kingdom in its regional analysis?
United Kingdom is included within Europe under the regional scope of analysis.
What are the sources referred to for analyzing United Kingdom?
Official statistics published by Food Standards Agency covering facility output, capacity utilization, and export trade flows are cited as primary reference sources.
What is the main demand theme linked to United Kingdom in its region coverage?
Europe demand is associated with export oriented product upgrading to satisfy stringent Western ingredient quality regulations.
Does the report cover Brazil in its regional analysis?
Brazil is included within Latin America under the regional coverage framework.
What is the main Brazil related demand theme in its region coverage?
Export driven product upgrading to meet North American and European safety standards is emphasized.
Which product formats or configurations are strategically important for Asia Pacific supply chains?
Powder formats and soluble extracts are prioritized due to lower storage risk and reduced logistics constraints across export channels.
What is Beta-glucans from Yeast and what is it mainly used for?
Beta-glucans from Yeast is a complex polysaccharide primarily used as an immunomodulatory ingredient in supplements, functional foods, and cosmetics manufacturing.
What does Beta-glucans from Yeast mean in this report?
Beta-glucans from Yeast refers to global production, trade, and industrial consumption of cell wall extracts in liquid, powder, and modified forms.
What is included in the scope of this Beta-glucans from Yeast report?
Scope covers extracts by form, key applications such as supplements and cosmetics, and end use industries including animal feed and nutrition.
What is excluded from the scope of this report?
Cereal and mushroom extracts, finished goods, and non industrial uses are excluded unless part of yeast hybrid blends.
What does market forecast mean on this page?
Market forecast represents a model based projection built on defined assumptions for strategic planning purposes.
How does FMI build and validate the Beta-glucans from Yeast forecast?
Forecast is developed using hybrid top down and bottom up modeling validated through trade data, capacity checks, and industry review.
What does zero reliance on speculative third party market research mean here?
Primary interviews and verifiable public datasets are used instead of unverified syndicated market estimates.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Beta-glucans from Yeast Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
